Belite Bio CFO gains 144,868 vested options

Belite Bio’s Chief Financial Officer Hao-Yuan Chuang acquired additional vested stock options tied to performance goals.

Rhea-AI Filing Summary

Belite Bio’s Chief Financial Officer Hao-Yuan Chuang acquired additional vested stock options tied to performance goals. On the satisfaction of a performance criterion on March 31, 2026, an option vested as to 144,868 ordinary shares under a grant originally made on December 23, 2020.

The option has an exercise price of $0.4386 per share and an expiration date of December 22, 2030. After this vesting event, the CFO holds options exercisable for a total of 289,736 ordinary shares under this grant.

Insider Trade Summary

Grant/Award: 144,868 shares

Grant/Award 1 txn

Insider Chuang Hao-Yuan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	144,868	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 289,736 contracts (Direct)

Footnotes (1)

1. F1. On December 23, 2020, the reporting person was granted an option which shall vest in installments upon satisfaction of certain performance criteria. 144,868 ordinary shares subject to the option that had previously vested remain exercisable. One of the performance criteria was met on 3/31/2026, resulting in vesting of the option as to additional 144,868 ordinary shares.

Key Figures

Newly vested options: 144,868 shares Total vested options after event: 289,736 shares Option exercise price: $0.4386 per share +1 more

4 metrics

Newly vested options 144,868 shares Options vesting on March 31, 2026 upon performance criterion

Total vested options after event 289,736 shares Total ordinary shares subject to the option now exercisable

Option exercise price $0.4386 per share Exercise price for the vested stock option grant

Option expiration date December 22, 2030 Expiration for the 289,736-share option grant

Key Terms

Stock Option (right to buy), performance criteria, vesting, Ordinary Shares

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

performance criteria financial

"shall vest in installments upon satisfaction of certain performance criteria"

vesting financial

"resulting in vesting of the option as to additional 144,868 ordinary shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Belite Bio (BLTE) report for its CFO?

Belite Bio reported that CFO Hao-Yuan Chuang acquired vested stock options over 144,868 ordinary shares. The vesting occurred when a performance criterion was met, increasing his exercisable options position under a 2020 grant.

How many Belite Bio (BLTE) shares are covered by the CFO’s vested options now?

Following the latest vesting, the CFO’s option grant covers 289,736 ordinary shares that are exercisable. This total combines 144,868 shares that had previously vested with an additional 144,868 shares that vested on March 31, 2026.

What is the exercise price of the Belite Bio (BLTE) CFO’s vested stock options?

The CFO’s vested stock options have an exercise price of $0.4386 per ordinary share. This price was set under the original option grant dated December 23, 2020, and applies to the full 289,736 vested shares.

When do the Belite Bio (BLTE) CFO’s vested options expire?

The vested stock options for Belite Bio’s CFO expire on December 22, 2030. After this expiration date, any unexercised portion of the 289,736 vested option shares will no longer be exercisable under the grant terms.

What triggered the new vesting of Belite Bio (BLTE) CFO’s options?

The new vesting was triggered when one of the performance criteria attached to the 2020 option grant was met on March 31, 2026. This event caused an additional 144,868 ordinary shares under the option to vest and become exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chuang Hao-Yuan

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.4386	03/31/2026		A		144,868		03/31/2026	12/22/2030	Ordinary Shares	144,868	$0	289,736(1)	D

Explanation of Responses:

1. On December 23, 2020, the reporting person was granted an option which shall vest in installments upon satisfaction of certain performance criteria. 144,868 ordinary shares subject to the option that had previously vested remain exercisable. One of the performance criteria was met on 3/31/2026, resulting in vesting of the option as to additional 144,868 ordinary shares.

	/s/ Hao-Yuan Chuang	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)